Scarica l'app Stockscreener
32.50
0.55%
-0.18
Dopo l'orario di chiusura:
32.49
-0.010
-0.03%
Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie
Assenagon Asset Management S.A. Purchases 128,619 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis Pharmaceuticals EVP Brian Birchler sells $176,580 in stock - MSN
Ionis Pharmaceuticals EVP Eric Swayze sells $235,678 in stock - MSN
Ionis Pharmaceuticals CEO Brett Monia sells $1.09 million in stock - MSN
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eric Swayze Sells 7,154 Shares - MarketBeat
Brett P. Monia Sells 33,445 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock - MarketBeat
Ionis Pharmaceuticals CFO sells stock worth $290,989 - MSN
Ionis Pharmaceuticals exec sells $144,861 in stock By Investing.com - Investing.com Australia
Ionis Pharmaceuticals EVP sells $232,407 in stock By Investing.com - Investing.com Australia
Ionis Pharmaceuticals EVP sells $213,889 in stock - MSN
Ionis Pharmaceuticals EVP sells $232,407 in stock - MSN
Ionis Pharmaceuticals exec sells $144,861 in stock - MSN
Bennett C. Frank of Ionis Pharmaceuticals sells $222,113 in stock - MSN
Ionis Pharmaceuticals EVP sells $241,628 in stock - MSN
Ionis Pharmaceuticals EVP Brian Birchler sells $176,580 in stock By Investing.com - Investing.com Australia
Ionis Pharmaceuticals EVP Eric Swayze sells $235,678 in stock By Investing.com - Investing.com South Africa
Ionis Pharmaceuticals CFO sells stock worth $290,989 By Investing.com - Investing.com South Africa
Ionis Pharmaceuticals EVP sells $241,628 in stock By Investing.com - Investing.com Canada
EVP, Chf Clinical Develop Ofcr Schneider Eugene converted options into 17,372 shares and sold $213,889 worth of shares (6,523 units at $32.79), increasing direct ownership by 23% to 58,508 units (SEC Form 4) - Quantisnow
Ionis Pharmaceuticals EVP sells shares worth $139,855 By Investing.com - Investing.com UK
Director Yang Michael J. converted options into 1,931 shares (SEC Form 4) - Quantisnow
Ionis Pharmaceuticals (NASDAQ:IONS) Hits New 12-Month LowTime to Sell? - MarketBeat
Why Ionis Pharmaceuticals (IONS) Is the Biotech Stock with Biggest Upside Potential - Insider Monkey
Familial Lipoprotein Lipase Deficiency Market to Continue - openPR
Retinitis Pigmentosa Pipeline Assessment 2024: Therapies, Clinical Trials, and Key Companies involved by DelveInsight | Biogen, Neurotech, Ionis Pharma, Nacuity Pharma, Allegro Ophthalmics, ID Pharma - Barchart
Amyotrophic Lateral Sclerosis Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Treatment Outlook | Biogen, GSK, Helixmith, Sanofi, Denali Therapeutics, Ionis Pharma, Brainstorm Cell - The Globe and Mail
Ionis Pharmaceuticals (NASDAQ:IONS) Receives Outperform Rating from Royal Bank of Canada - MarketBeat
U.S, Europe And GCC Antisense Oligonucleotide (ASO) - openPR
Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum - Marketscreener.com
Ionis enters new chapter in 2025 as commercial-stage biotech wit - GuruFocus.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by International Assets Investment Management LLC - MarketBeat
Ionis Pharma stock hits 52-week low at $33.33 amid market challenges - Investing.com Australia
US FDA approves Ionis Pharma's genetic disorder drug - AOL
Ionis Pharmaceuticals (NASDAQ:IONS) Sets New 1-Year LowShould You Sell? - MarketBeat
Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight - GlobeNewswire Inc.
Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference - The Malaysian Reserve
Vanguard Group Inc's Strategic Acquisition of Ionis Pharmaceuticals Shares - GuruFocus.com
Ionis to present at 43rd Annual J.P. Morgan Healthcare Conferenc - GuruFocus.com
Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference – Company Announcement - Financial Times
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected - Benzinga
Otsuka and Ionis’ donidalorsen accepted for EMA review - The Pharma Letter
Objective long/short (IONS) Report - Stock Traders Daily
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic - Benzinga
Ionis Pharmaceuticals Initiates Phase 3 Study of Olezarsen to Treat Severe Hypertriglyceridemia - Marketscreener.com
1.44%
7.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):